Corcept Therapeutics
Headquarters country
United States
Registry sponsor category
Industry
- Other names
- Corcept Therapeutics
- Company name
- Corcept Therapeutics
- Organisation type
- Industry
- Registered legal name
- Corcept Therapeutics Incorporated
- US industry code (SIC)
- Pharmaceutical preparations
- Registry sponsor category
- Industry
- Website
- http://www.corcept.com/
- SEC filer number (CIK)
- 0001088856
- Legal Entity Identifier (LEI)
- 529900EO9LUTFMZ7FF90
- Wikidata ID
- Q15734041
Related records
Trials (79)
- A 4-week Study of Mifepristone in the Prevention of Risperidone-induced Weight Gain in Healthy Male Volunteers
- A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)
- A Phase I Study to Determine the Effect of Mifepristone on the Pharmacokinetics of Fluvastatin in Healthy Volunteers
- A Study Designed to See How [14C]-CORT125134 is Taken up, Broken Down and Removed From the Body
- A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Obese Adult Patients With Schizophrenia While Taking Antipsychotic Medications (GRATITUDE II)
- A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)
- A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
- A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
- A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome
- A Study of the Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas
- A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome
- A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adults With Schizophrenia or Bipolar Disorder Treated With Antipsychotic Medications
- A Study to Confirm Recurrent or Persistent Cushing's Syndrome in Patients With Signs or Symptoms of Hypercortisolemia
- A Study to Determine the Relative Bioavailability of Two New Relacorilant Capsule Variants
- A Study to Evaluate the Effect of Food on the Oral Bioavailability of Relacorilant in Healthy Subjects
- A Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Relacorilant
- A Study to Evaluate the Pharmacokinetics of the CORT125134 Phase 2 Formulation in Healthy Male Subjects
- A Study to Evaluate the Pharmacokinetics of the Current Capsule Formulation of CORT125134 in Healthy Subjects
- A Sub Study of the Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)
- A Two-Week Study of the Efficacy and Safety of Mifepristone in the Prevention of Olanzapine-Induced Weight Gain